Bonothyrk A-21 Parathyroid Peptide Bioregulator

Descrizione Del Prodotto

1. Classification and Chemical Overview

Bonothyrk A-21 Parathyroid Peptide Bioregulator is an organ-specific biological response modifier categorized within the cytomax family of natural peptide bioregulators. Chemically, the active constituent comprises a purified, low-molecular-weight polypeptide fraction isolated from the parathyroid glandular tissue of young mammalian livestock, predominantly bovine donors (Bos taurus). The extraction protocol utilizes gentle acetic acid digestion coupled with successive ultrafiltration stages to isolate polypeptide fractions with an upper molecular mass threshold restricted below $5\text{ to }10\text{ kDa}$. The active fraction consists of ultra-short oligopeptides spanning 2 to 6 amino acid sequences, trace endogenous nucleopeptides, and organ-specific regulatory signalling motifs. Synthetic models commonly emulate these targeted sequences via solid-phase synthesis using short di-, tri-, or tetrapeptide motifs. The formulation is presented in hard gelatin or hydroxypropyl methylcellulose (HPMC) capsules containing standard pharmaceutical excipients such as microcrystalline cellulose, lactose, and calcium stearate.

Within the United Kingdom regulatory framework, Bonothyrk A-21 possesses no marketing authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA). It is not scheduled as a Prescription Only Medicine (POM), Pharmacy (P) medicine, or General Sales List (GSL) drug under the Human Medicines Regulations 2012, nor is it catalogued in the British National Formulary (BNF). Consequently, Bonothyrk A-21 is commercialised within the UK strictly as a non-medicinal food supplement or chemical research material governed by the Food Safety Act 1990 and the Nutrition and Health Claims (England) Regulations. In accordance with domestic trading standards and statutory food supplement legislation, commercial distributors are legally prohibited from articulating therapeutic or medicinal claims regarding the prevention, diagnosis, mitigation, or treatment of clinically established endocrine or metabolic bone pathologies (such as primary or secondary hyperparathyroidism, hypoparathyroidism, pseudohypoparathyroidism, osteoporosis, osteomalacia, or severe calcium dyshomeostasis).

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of Bonothyrk A-21 is rooted in the tissue-specific epigenetic model of short-chain peptide bioregulation, operating primarily via nuclear transactivation and cellular homeostasis within parathyroid principal (chief) cells:

• Epigenetic and Transcriptional Regulation: Due to low molecular mass, compact hydrodynamic volume, and neutral-to-amphiphilic characteristics, the ultra-short oligopeptides within Bonothyrk A-21 penetrate the plasma membranes of parathyroid chief cells and translocate through the nuclear pore complex into the nucleoplasm. Within the nucleus, these peptides interact site-specifically with the major and minor grooves of double-stranded genomic DNA and nucleosomal core histones. This interaction induces conformational modifications in local chromatin architecture, converting transcriptionally quiescent heterochromatin into transcriptionally active euchromatin, recruiting RNA polymerase II, and modulating the transcription of functional genes essential for parathyroid glandular competence.

• Modulation of Parathyroid Cellular Homeostasis: Preclinical in vitro models demonstrate that parathyroid peptide complexes stimulate the transcription of structural proteins and signaling components fundamental to parathyroid physiology, including the calcium-sensing receptor (CASR) and endogenous parathyroid hormone (PTH) gene expression pathways. Rather than acting as exogenous hormonal surrogates or autonomous receptor agonists, Bonothyrk A-21 appears to support intrinsic cellular protein synthesis, promoting the physiological capacity of chief cells to perceive extracellular ionized calcium concentrations and maintain basal secretory balance without triggering hyperplastic cellular proliferation.

• Regulation of Bone Remodeling and Calcium Turnover: At the tissue level, physiological stabilization of parathyroid signaling optimizes the homeostatic balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. By maintaining appropriate paracrine and endocrine signalling cues, these peptides help preserve bone mineral density, supporting the structural integrity of trabecular and cortical bone compartments and modulating osteocalcin and alkaline phosphatase expression.

• Cytoprotection and Apoptosis Resistance: Exposure to short parathyroid peptides attenuates oxidative stress-induced cell death in glandular tissue. This cytoprotective action is mediated by downregulating pro-apoptotic executioners (caspase-3 and Bax), preserving mitochondrial inner membrane integrity ($\Delta\Psi_m$), and transcriptionally upregulating endogenous antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase.

3. Approved UK Clinical Indications and Therapeutic Scope

Bonothyrk A-21 possesses no approved clinical indications in the United Kingdom. It has not undergone the rigorous, randomized, double-blind, multicentre Phase I–III clinical trials required by the MHRA to establish pharmaceutical quality, therapeutic efficacy, or toxicological safety.

The National Institute for Health and Care Excellence (NICE) does not endorse, recommend, or integrate Bonothyrk A-21 into any formal clinical pathway. It is entirely absent from clinical guidelines governing osteoporosis: assessing the risk of fragility fracture (CG146), primary hyperparathyroidism: diagnosis and management (NG132), and chronic kidney disease: assessment and management (NG203).

The application of Bonothyrk A-21 is confined strictly to non-clinical consumer wellness contexts and preliminary laboratory research. In exploratory literature and private functional health sectors, it is investigated for:

• Nutritional support of the parathyroid gland during age-related bone mineral density decline (osteopenia).

• Assisting physiological bone turnover and calcium metabolism in post-menopausal populations.

• Convalescent nutritional support following non-pathological musculoskeletal strain, fractures, or intense physical training.

• Preclinical animal models examining bone microarchitecture preservation and mineral homeostasis under conditions of physical immobilisation or experimental parathyroid insufficiency.

Bonothyrk A-21 holds no status within the NHS drug tariff, cannot be prescribed on NHS FP10 forms, and must never replace validated clinical treatments, including recombinant parathyroid hormone analogues (teriparatide), antiresorptive bisphosphonates (alendronic acid, zoledronic acid), receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (denosumab), calcimimetics (cinacalcet), or active vitamin D metabolites (alfacalcidol, calcitriol).

4. Pharmacokinetic Profile and Metabolic Fate

Because Bonothyrk A-21 is formulated as an oral capsule, its pharmacokinetic disposition is determined by gastrointestinal transport and physiological peptide clearance kinetics:

• Absorption: Crude protein macromolecules undergo extensive cleavage in the stomach by pepsin and in the small intestine by pancreatic endopeptidases (trypsin, chymotrypsin). However, the ultra-short di-, tri-, and tetrapeptides present in Bonothyrk A-21 exhibit structural resistance to complete brush-border aminopeptidase degradation. These intact short peptide sequences cross the apical enterocyte membrane into the portal circulation via the low-affinity, high-capacity proton-coupled peptide transporter 1 (PEPT1). Peak plasma concentrations ($T_{max}$) of intact circulating oligopeptides typically occur within 20 to 50 minutes following oral ingestion.

• Distribution: Following mesenteric absorption and portal transit, the peptides enter the systemic vascular compartment. With a low molecular weight and hydrophilic properties, the apparent volume of distribution ($V_d$) corresponds closely to total extracellular fluid volume. Preclinical biodistribution assays demonstrate selective tropism toward parathyroid glandular tissue and mineralised osseous compartments, crossing regional microvascular beds to access parathyroid chief cells and skeletal cellular targets. Plasma protein binding is negligible ($<5\%$).

• Biotransformation: Bonothyrk A-21 does not undergo hepatic clearance via the cytochrome P450 (CYP450) microsomal monooxygenase system (e.g., CYP1A2, CYP2D6, CYP3A4). Systemic clearance is mediated entirely by circulating plasma aminopeptidases, carboxypeptidases, and cellular endopeptidases, which rapidly hydrolyse peptide bonds into native constituent individual L-amino acids (such as L-alanine, L-glutamic acid, and L-aspartic acid). These amino acids enter endogenous amino acid turnover and protein synthesis pools.

• Elimination: Systemic elimination of intact peptides is rapid, with an effective half-life ($t_{1/2}$) ranging between 15 and 60 minutes. Direct renal excretion of intact macromolecular peptides is negligible; end-stage metabolites are cleared as urinary urea, with trace carbon atoms exhaled as carbon dioxide via respiratory gas exchange.

5. Physiological Effects and Adverse Event Spectrum

The primary physiological effect documented in preclinical investigations is the normalization of parathyroid glandular activity, characterized by stabilized basal secretion of parathyroid hormone, preservation of serum ionized calcium within physiological ranges, and modulated bone turnover markers without triggering excessive bone resorption. In animal models of experimental osteopenia, these agents demonstrate structural maintenance of trabecular microarchitecture, preserved cortical thickness, and improved mechanical load resistance without inducing parathyroid chief cell hyperplasia.

Because Bonothyrk A-21 has not undergone structured, large-scale Phase I–IV clinical pharmacovigilance surveillance, documentation of adverse drug reactions is derived primarily from observational cohorts and preclinical animal toxicology:

• Very Common ($\ge 1/10$): None documented in clinical literature.

• Common ($1/100$ to $<1/10$): Mild, self-limiting gastrointestinal symptoms following oral intake, including transient nausea, epigastric fullness, mild dyspepsia, and abdominal bloating.

• Uncommon ($1/1,000$ to $<1/100$): Transient sensations of mild cephalalgia; mild, localized cutaneous pruritus or macular rash; transient subjective sensations of muscular weakness or fatigue.

• Rare ($1/10,000$ to $<1/1,000$): Type I immediate allergic hypersensitivity reactions (urticaria, angioedema, or bronchospasm), principally triggered in atopic individuals sensitized to bovine structural protein residues.

• Biological and Diagnostic Hazards: Unregulated preparations derived from non-certified mammalian sources carry theoretical risks of transmissible spongiform encephalopathies (TSE/BSE) if origin verification is absent. Crucially, self-administering unlicensed bioregulators to manage progressive bone pain, recurrent nephrolithiasis, or neuromuscular hyperexcitability presents a serious clinical hazard by potentially delaying diagnostic evaluation for autonomous parathyroid adenomas, malignant hypercalcaemia, severe osteoporosis, or chronic renal failure.

6. Contraindications, Drug Interactions, and Clinical Precautions

The handling and administration of Bonothyrk A-21 require strict adherence to fundamental endocrine and pharmacological safety parameters:

• Contraindications:

  • Documented hypersensitivity or history of allergic anaphylaxis to bovine-derived biological substances, gelatin, or any formulation excipients.

  • Hyperparathyroidism and Hypercalcaemia: Absolute contraindication in patients with diagnosed primary, secondary, or tertiary hyperparathyroidism, autonomous parathyroid adenomas, parathyroid carcinoma, or pre-existing hypercalcaemia (serum adjusted calcium $>2.60\text{ mmol/L}$). Modulating cellular transcription or glandular activity in autonomous hypersecretory states carries unpredictable metabolic risks.

  • Malignancy-associated skeletal disease: Absolute contraindication in individuals with bone metastases, multiple myeloma, or skeletal malignancies, due to heightened risks of exacerbating pathological osteolysis or malignant hypercalcaemia.

  • Severe Nephrolithiasis or Renal Impairment: Contraindicated in patients with active calcium-containing nephrolithiasis or end-stage renal disease (CKD Stages 4–5), where altered calcium-phosphate balance requires rigorous specialist management.

  • Pregnancy and lactation: Absolute contraindication due to an absence of embryotoxicity, teratogenicity, and developmental reproductive safety data, alongside unknown secretion into human breast milk.

  • Paediatric population: Contraindicated in infants, children, and adolescents under 18 years due to an absence of safety and developmental data regarding the maturing paediatric skeleton and epiphyseal growth plates.

• Drug Interactions:

  • Teriparatide and PTH Analogues: Concurrent administration may cause unpredictable pharmacodynamic interactions or alter endogenous parathyroid receptor responsiveness.

  • Calcimimetics (e.g., cinacalcet): Concomitant use may interfere with the pharmacological allosteric regulation of the calcium-sensing receptor.

  • Bisphosphonates, Denosumab, and Calcium/Vitamin D Supplements: No direct pharmacokinetic interactions via CYP450 enzymes exist; however, patients receiving licensed therapies for osteoporosis must not interrupt or modify their regimens.

  • Thiazide Diuretics: Concurrent administration requires monitoring, as thiazides decrease urinary calcium excretion, which can unmask subclinical hypercalcaemic states.

  • Cytochrome P450 interactions: There are no documented pharmacokinetic induction or inhibition interactions with hepatic CYP450 isoenzymes.

• Clinical Precautions:

  • Endocrine Alarm Symptoms (“Red Flags”): Patients presenting with symptoms indicative of severe hypercalcaemia—such as polyuria, polydipsia, persistent constipation, abdominal pain, severe bone pain, muscle weakness, confusion, or cardiac arrhythmias—mandate emergency medical assessment and serum electrolyte profiling.

  • Biochemical Monitoring: Individuals presenting with persistent skeletal fragility, recurrent low-trauma fractures, or unexplained neuromuscular tetany require formal medical evaluation, including serum adjusted calcium, phosphate, alkaline phosphatase, 25-hydroxyvitamin D, intact PTH, and DEXA bone densitometry, rather than non-directed nutritional supplementation.

  • Source Purity: Clinicians and researchers must verify that natural mammalian extracts possess documented batch-specific certification confirming extraction from BSE-free herds and compliance with UK/EU biological safety criteria.

Ulteriori Informazioni